RNA Therapeutics Fundamental Analysis

RNA Therapeutics Overview

RNA therapeutics market has received funding of over USD 16 billion since 2011, highlighting the R&D progress in this field. These investments are likely to grow rapidly in the coming decade, driven by technological advancements and drug approvals.

Tap or click on the images for smart insights on RNA Therapeutics Market

RNA therapeutics are known to target specific genetic sequences of individual patients, in order to provide more effective treatment options for a wide range of disorders, with fewer side effects. These therapies are currently being developed using different types of RNA-based molecules, including coding RNAs (such as mRNA) and non-coding RNAs (such as interfering RNAs (RNAi), antisense oligonucleotides (ASO) and RNA aptamers).

Tap or click on the images for smart insights on RNA Therapeutics Market

RNA therapies have emerged as a promising treatment modality, with the potential to target and alter genes, modulate protein function and broaden the range of druggable targets, thereby, paving way for new avenues in disease diagnosis and treatment. Driven by the rise in government initiatives for early commercialization of pipeline therapeutics and active involvement of RNA therapeutics investors, we anticipate a variety of next generation RNA therapeutics to be developed, presenting lucrative investment opportunities for both short- and long-term investors.

Tap or click on the images for smart insights on RNA Therapeutics Market

Recent Funding and Investment in RNA Therapeutics Companies

Several investments have taken place in the field of RNA Therapeutics, and we outline some of these below.

• In May 2025, Haya Therapeutics raised USD 65 million in Series A funding, led by Angelini Ventures and Invivo Partners. The funds will be used for clinical development of their long non-coding RNA (lncRNA) targeting candidate HTX-001 under development for heart failure.
• In January 2025, Neumirna Therapeutics raised EUR 20 million in a Series A funding round led by Index Ventures. The funds will be used for clinical development of their lead antisense oligonucleotide candidate NMT.001 under development for drug resistant epilepsy.  
• In October 2024, City Therapeutics launched operations with a Series A funding of USD 135 million led by ARCH Venture Partners. The company is working on development of next-generation small interfering RNAs (siRNAs) therapeutics.

RNA Therapeutics Fundamental Analysis: Report Deliverables

RNA Therapeutics Fundamental Analysis Major Takeaways

The “Investor Series: Opportunities in RNA Therapeutics Market” report provides detailed information on the RNA therapeutics market, covering the various types of RNA therapeutics, including RNAi therapeutics and technology, RNA aptamers, and mRNA therapies and mRNA vaccines. It offers a technical and financial perspective on how the opportunity in this domain is likely to evolve, in terms of future business success, till 2035. Key takeaways of the market report are briefly discussed below.

What Are Some Approved RNA Therapeutics?

The development of RNA-based therapeutics initially gained momentum in 2004, with the approval of the first RNA based therapeutic modality, Macugen (developed by Eyetech Pharmaceutics and Pfizer), which was intended for the treatment of neovascular age-related macular degeneration. However, despite the potential benefits offered by this therapeutic modality, the unique challenges associated with drug delivery, manufacturing, logistics and storage led to a decline in the popularity of RNA therapies post the initial rise in early 2000s.

Consequently, some activity in this domain was reported in 2018, when ONPATTRO (developed by Alnylam Pharmaceuticals) received approval from USFDA and EMA; this RNAi therapy was intended for the treatment of hereditary transthyretin amyloidosis (hATTR), a rare and life-threatening disorder.

Subsequently, it was the phenomenal success of mRNA therapies against the COVID-19 pandemic which fully reignited the interest of general public, patients, healthcare providers and investors in this market. For instance, in 2021 and 2022, two mRNA vaccines intended for COVID-19 received emergency use approvals from the USFDA; these were BNT162b2 (developed by BioNTech and Pfizer) and mRNA-1273 (developed by Moderna).  

How Has the Funding Shaped the RNA Therapeutics Industry Growth?

Numerous start-ups have been established in the last few years, indicating the growing interest in this sector. Owing to the rising demand for better therapeutic options and increasing adoption rate of such therapies, the investment focus for RNA therapeutics has increased significantly. In fact, since 2011, a total of over USD 16 billion was raised by RNA-based drug developers to advance their pipeline candidates.

It is worth highlighting that, amongst the RNA therapeutics investors, majority of the investments have been led by mRNA vaccines investors and mRNA therapeutics investors. This is followed by RNAi therapeutics investors and RNA aptamers investors.

What are the Growth Drivers for Investment in RNA Therapeutics Industry?

RNA therapeutics have shown promising results in the treatment of rare diseases, particularly neurological and hepatic diseases. In fact, 80% of such therapies being evaluated in late stages of clinical development have received the orphan drug designation. This further showcases the potential of RNA therapeutics to actualize the concept of personalized medicine in the foreseen future.

Scope of the RNA Therapeutics Fundamental Analysis

The market report presents an in-depth analysis, highlighting the RNA therapeutics industry financials. Amongst other elements, the market report includes:

• An introduction to RNA therapeutics, highlighting information on products that have either been marketed / are under development. In addition, the report highlights prominent barriers to the development and success of RNA therapies, and the opinions of representatives from key stakeholder companies involved in this domain.
• A detailed analysis of RNA therapeutics focused companies that were established post-2007, featuring key insights on the observed trends related to the basic company parameters, such as year of establishment, location of headquarters, company size and type of venture.
• An assessment of the various products, offered by innovator companies engaged in this domain, based on number of products and type of product. Based on the aforementioned insights, we have developed a quantitative perspective on the relative health (based on basic company details, product portfolio, financing activity, estimated revenues and profits) of different innovator companies, using a proprietary scoring criterion, which was informed via secondary research.
• An informed perspective on the value proposition of companies captured in the report based on multiple relevant aspects, namely therapy-related aspect, developer-related aspect, technology-related aspect, and patient-related aspect.
• A company competitiveness analysis, highlighting a quantitative basis for comparing the strengths / contributions of various industry stakeholders that are involved in the development of RNA therapeutics. It is worth mentioning that this analysis is based on the insights generated from the abovementioned relative health indexing and value proposition analysis.
• A detailed analysis of the funding and investment activity that has taken place in this domain, since 2011. It also includes category-wise financing trends, describing the relative maturity (in terms of number of funding instances and total capital raised) of innovator companies mentioned in the report. Further, it features a list of leading investors in RNA therapeutics market, based on their participation in financing activity in this industry segment.
• A proprietary analysis defining a basis for estimating the relative valuation of private companies, among the innovators discussed in this report. The value statements generated under this analytical framework were based on information gathered via secondary research, for a sample set of companies. Key inferences drawn from the sample set were then extrapolated to generate the likely valuation estimates for all companies in the dataset.
• An elaborate review of the overall RNA therapeutics market from a financial perspective, including detailed fundamental (insights from the balance sheet and key financial ratios) and technical analysis (insights from historical and recent stock price variations as well as analysis using popular stock performance indicators) of financial data of the publicly listed companies within the innovators landscape dataset.
• Elaborate profiles of the prominent public ventures engaged in the development of RNA therapeutics, featuring a brief overview of the company, details on its management team, insights generated from its balance sheet (if available), information on product portfolio, a section on recent developments and key financial details (including company investment highlights, company fundamental and company technical analysis).
• A case study on the assessment of business risks, based on some of the major risk categories that are usually discussed in the industry, namely operations-related risks, business-related risks, financial / asset-related risks, product / technology-related risks, and industry specific risks and other risks (social, economic, environmental and political risks).
• A detailed market forecast analysis, highlighting the likely evolution of the RNA therapeutics market in the short to mid-term and long term, over the period 2023-2035. Further the year-wise projections of the current and future opportunity have been segmented based on relevant parameters, such as type of therapy (miRNA therapies, siRNA therapies, mRNA therapies, mRNA vaccines and RNA aptamers), therapeutic area (infectious diseases, metabolic disorders, oncological disorders, genetic disorders, and other disorders), route of administration (intramuscular, intravenous, intranasal and other routes of administration) and key geographies (North America, Europe, Asia, Latin America, Middle East and North Africa, and rest of the world). In order to account for future uncertainties in the market and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.
• A case study where investors have exited various RNA therapeutics-related ventures, offering insights on returns on investment received (based on availability of data). Leveraging the abovementioned details, the report offers an informed opinion on the future outlook for investors in the RNA therapeutics market.
• A key acquisition targets analysis, based on the insights generated during the course of this study, highlighting some of the promising early-to-mid stage business ventures that are likely to be acquired / merged.

Key Questions Answered

What type of RNA therapeutics are being offered by the innovator companies?

What are the key value propositions offered by players engaged in the RNA therapeutics domain?

What is the relative competitiveness of different players engaged in the development of RNA therapeutics?

Who are the key investors that are actively supporting the development and commercialization of RNA therapeutics?

What are the anticipated fundamental and technical trends of financial data of publicly listed companies within the innovator landscape?

Who are the potential acquisition targets for investors in the RNA therapeutics domain?

What are the major risks for investors seeking to tap into the RNA therapeutics domain?

What is the estimated return on investments received by the investors?

How is the current and future market opportunity related to RNA therapeutics likely to be distributed across key market segments?